Flash Finance

Sigachi Industries LimitedSIGACHICorporate

Pharmaceuticals - Indian - Bulk Drugs & Formln Latest results: Jun 2026 15 quarters of data
Consolidated Standalone
₹27.52
MCap ₹1,053 Cr · P/E 40.3
Sigachi Industries Limited — Stock analysis & AI research Sigachi Industries Limited — Multibagger AI analysis Sigachi Industries Limited — Seasonality — best & worst months Sigachi Industries Limited — Technical setup — score, trend, support & resistance Sigachi Industries Limited — Live exchange announcements
📈 Bollinger Squeeze Stocks📈 20-Day Breakdown Stocks 🏭 Pharma sector
AI-assisted data: figures and text on this page are extracted from public quarterly filings with AI assistance, checked automatically and overseen by our editorial team (human in the loop). They may still contain errors or omissions. Verify critical numbers against official company / SEBI / NSE / BSE filings before making any decision. Educational information only, not financial advice.
₹98 Cr
Sales · Jun 2026
-11.4% YoY
₹13 Cr
Operating Profit · Jun 2026
-45.1% YoY
13.4%
OPM % · Jun 2026
-38.0% YoY
₹7 Cr
Net Profit · Jun 2026
+106.6% YoY
₹0.17
EPS · Jun 2026
+106.6% YoY

📝 Sigachi Industries Limited — results explained

Quarter ended June 2026 (Q1 FY27)

Sigachi Industries Limited reported revenue of ₹98 crore for the quarter ended June 2026 (Q1 FY27), down 11.4% from ₹111 crore in the same quarter last year, and up 6.7% sequentially over the March 2026 quarter.

The company swung to a net profit of ₹7 crore from a net loss of ₹99 crore a year earlier. Earnings per share (EPS) came in at ₹0.17.

Operating profit stood at ₹13 crore — an operating margin (OPM) of 13.4%, compared with 21.6% in the year-ago quarter.

Full year and trailing twelve months

For the full year FY26, Sigachi Industries Limited posted revenue of ₹379 crore, a decline of 7.1% over FY25, with a net loss of ₹80 crore.

On a trailing-twelve-month (TTM) basis, revenue stands at ₹366 crore with a net profit of ₹26 crore.

Valuation snapshot

At the current price of ₹27.52, SIGACHI has a market capitalisation of ₹1,053 crore and a trailing P/E of about 40.3.

Within the Pharmaceuticals - Indian - Bulk Drugs & Formln industry, it is the 25th-largest of the 47 companies we track by market value.

Shareholding pattern

As of Jun 2026, promoters held 36.69%, foreign institutional investors (FIIs) 1.25%, public shareholders 62.05% of Sigachi Industries Limited.

📈 Share price & events

📊 Quarterly trend

₹ crore · OPM % on right axis

🎯 Key metrics

price-linked ratios use the latest close
Valuation
Market Cap ?
₹1,053 Cr
Current Price ?
₹27.5
P/E ?
40.32above ind
Industry P/E ?
37.20
P/B ?
2.21
P/S ?
2.87
P/FCF ?
350.87
Enterprise Value ?
₹1,179 Cr
EV/EBITDA ?
30.07
PEG ?
N/A
Earnings Yield ?
1.8%
Dividend Yield ?
0.36%
Profitability & Returns
Sales (TTM) ?
₹366 Cr
OPM ?
10.7%
Profit after tax (TTM) ?
₹26 Cr
EPS (TTM) ?
₹0.68
ROCE ?
7.0%
ROE ?
5.5%
ROA ?
3.6%
Growth
Sales — latest qtr ?
₹98 Cr
PAT — latest qtr ?
₹7 Cr
YoY qtr sales growth ?
-11.4%
YoY qtr profit growth ?
106.6%
Sales growth (3y) ?
9%
Sales growth (5y) ?
15%
Profit growth (3y) ?
-3%
Profit growth (5y) ?
6%
Financial Health
Debt ?
₹126 Cr
Debt to Equity ?
0.26
Interest Coverage ?
2.6
Current Ratio ?
N/A
Ownership
Promoter holding ?
36.69%
Change in promoter holding ?
-7.45%
Pledged percentage ?
N/A
Market
Return 3 months ?
10.0%
Return 6 months ?
17.9%

🗓️ Quarterly results (15 quarters · ₹ Cr)

same fiscal quarter as Jun bestweakest per row · for costs (interest, NPAs) low is best
Metric Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026 YoY % QoQ %
Sales 6976787977848010910511411184929298 -11.4% +6.7%
Operating Profit 1414151316151618211924771213 -45.1% +7.9%
Other Income 1221272152243000 -88.7% +133.4%
Interest 111222323325332 +1.8% -25.6%
Depreciation 222223234447344 -8.3% -4.2%
Profit Before Tax 12121411141713281614-99-91168 +107.9% +37.4%
Net Profit 1091081112922107-9912357 +106.6% +32.5%
EPS 3.203.073.302.720.340.370.280.660.290.18-2.590.310.080.130.17 +106.6% +30.8%
OPM % 20.4% 18.4% 19.5% 16.8% 20.6% 17.9% 20.5% 16.5% 20.2% 16.5% 21.6% 7.9% 7.8% 13.2% 13.4% -38.0% +1.5%

📆 Annual results (₹ Cr, FY = Apr–Mar)

Metric FY25 FY26 TTM YoY %
Sales ₹408 Cr ₹379 Cr ₹366 Cr -7.1%
Operating Profit ₹74 Cr ₹50 Cr ₹39 Cr -32.7%
OPM % 18.21% 13.19% 10.70% -27.6%
NPM % 11.69% -20.99% 7.13% -279.6%
Other Income ₹20 Cr ₹8 Cr ₹4 Cr -61.5%
Depreciation ₹13 Cr ₹18 Cr ₹18 Cr +42.2%
Interest ₹11 Cr ₹12 Cr ₹12 Cr +15.2%
EBIT ₹61 Cr ₹32 Cr ₹21 Cr -48.4%
PBT ₹71 Cr ₹-184 Cr ₹-77 Cr -359.7%
Tax ₹23 Cr ₹-2 Cr ₹-1 Cr -108.6%
Net Profit ₹48 Cr ₹-80 Cr ₹26 Cr -266.9%
EPS ₹1.41 ₹-2.07 ₹0.69 -246.8%
Material Cost ₹198 Cr ₹105 Cr ₹95 Cr -46.9%
Employee Cost ₹58 Cr ₹34 Cr ₹42 Cr -40.5%
Extraordinary Items — ₹-122 Cr ₹-1 Cr —

🏛️ Balance Sheet (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Equity Capital 31333838 +0.0%
Reserves 235377521438 -15.9%
Borrowings 68135113126 +11.5%
Other Liabilities 356474123 +66.2%
Total Liabilities 369609746725 -2.8%
Fixed Assets 122139254211 -16.9%
CWIP 3591527 +440.0%
Investments 2102102139 +36.3%
Other Assets 210276385348 -9.6%
Total Assets 369609746725 -2.8%

💧 Cash Flow (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
CFO/OP 70%40%67%102% +52.2%
Cash from Operating Activity 28153644 +22.2%
Cash from Investing Activity -93-158-90-89 +1.1%
Cash from Financing Activity 2616370-1 -101.4%
Net Cash Flow -392015-46 -406.7%
Free Cash Flow -72-67-63 +150.0%

➗ Ratios (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Debtor Days 115126120119 -0.8%
Inventory Days 89777167 -5.6%
Days Payable 54696188 +44.3%
Cash Conversion Cycle 15013513098 -24.6%
Working Capital Days 87669625 -74.0%
ROCE % 19%14%13%7% -46.2%

👥 Shareholding (latest 5 periods)

Metric Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026 % Chg
Promoters 44.14%40.48%39.70%36.69%36.69% +0.0%
FIIs 2.89%3.10%3.33%1.31%1.25% -4.6%
Public 52.97%56.41%56.97%62.01%62.05% +0.1%
No. of Shareholders 1,51,2062,05,2661,94,7771,94,5591,88,986 -2.9%

⚖️ Peer comparison

Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln · top 25 of 47 companies · full page →
# Company CMP MCap (Cr) P/E Sales TTM NP TTM OPM% NPM% Sales YoY% NP YoY% Qtr Rev Δ% Qtr NP Δ%
1 AKUMS Akums Drugs ₹784.55 12,012 41.2 4,502 293 12.6% 6.5% 5.9% -25.5% 13.9% 56.1%
2 STAR Strides Pharma ₹1,085.00 10,001 26.7 3,636 389 25.4% 10.7% -20.4% 99.0% 11.2% 50.0%
3 BLUEJET Blue Jet ₹565.05 9,802 36.9 884 265 36.3% 30.0% 8.0% 0.7% -17.5% -14.3%
4 AARTIPHARM Aarti Pharmalabs ₹828.30 7,511 36.1 1,957 208 22.0% 10.6% 1.5% -26.9% 42.4% 39.2%
5 SUPRIYA Supriya Lifescience ₹870.30 7,004 35.3 873 198 33.2% 22.7% 18.9% 11.1% 30.8% -30.9%
6 INNOVACAP Innova Captab ₹1,199.30 6,863 13.8 5,779 497 14.6% 8.6% 355.1% 277.4% 33.9% 42.3%
7 MOREPENLAB Morepen Laboratories ₹123.35 6,759 48.0 1,951 141 9.4% 7.2% -0.3% -18.3% 34.1% 394.0%
8 IOLCP IOL Chemicals ₹201.19 5,905 35.2 2,523 168 12.3% 6.7% 11.5% 36.6% 37.1% 89.8%
9 FDC FDC ₹350.20 5,702 19.5 2,191 291 15.3% 13.3% 3.0% 4.8% 3.0% 9.5%
10 NOVARTIND Novartis India ₹2,257.80 5,575 57.0 371 97 27.6% 26.2% -0.3% -6.9% 18.2% 14.3%
11 ORCHPHARMA Orchid Pharma ₹1,058.75 5,370 236.9 812 22 5.1% 2.7% -11.9% -76.4% 0.2% 25.4%
12 RPGLIFE RPG Life ₹2,865.90 4,740 39.7 735 120 21.1% 16.3% 8.4% -36.9% 15.8% 16.3%
13 ZOTA Zota Health ₹1,232.70 4,269 — 609 -104 0.6% -17.1% 84.6% -29.8% 66.9% -213.9%
14 GUFICBIO Gufic Biosciences ₹419.85 4,210 57.3 974 74 16.9% 7.6% 14.7% -9.1% 14.9% 86.0%
15 UNICHEMLAB Unichem Laboratories ₹526.70 3,708 12.2 2,308 305 9.9% 13.2% 6.2% 74.1% 20.1% 496.1%
16 INDSWFTLAB Ind-Swift Laboratories ₹374.00 3,252 55.4 665 57 9.0% 8.6% 235.3% 10.1% 32.3% -88.7%
17 ADVENZYMES Advanced Enzyme ₹293.25 3,249 19.8 750 172 29.8% 22.9% 17.1% 29.6% 2.1% -4.6%
18 SOLARA Solara Active ₹667.00 3,218 85.6 1,535 37 15.2% 2.4% 6.6% -1470.4% 33.1% 381.8%
19 DCAL Dishman Carbogen ₹162.08 2,541 157.6 2,902 16 16.7% 0.6% 8.1% 2655.7% -4.3% -351.7%
20 INDOCO Indoco Remedies ₹254.59 2,347 n/m 1,872 3 8.8% 0.2% 10.7% -26.5% 6.5% 280.0%
21 PANACEABIO Panacea Biotec ₹368.55 2,257 — 673 -9 0.3% -1.3% 14.4% 17.9% 19.7% -44.4%
22 REMUS Remus Pharma. ₹1,911.30 2,252 91.1 94 25 31.7% 26.7% — — 13.3% 21.4%
23 SAKAR Sakar Healthcare ₹987.40 2,167 61.0 272 36 28.5% 13.3% 41.9% 71.8% 38.4% 120.2%
24 JAGSNPHARM Jagsonpal Pharmaceuticals ₹227.53 1,501 33.3 294 45 20.7% 15.4% 6.9% -22.2% 8.5% 20.4%
25 SIGACHI Sigachi Industries ₹28.58 1,093 49.2 471 26 9.8% 5.6% -2.1% -217.5% -5.4% 108.1%
❓ Frequently asked questions
What was Sigachi Industries Limited's revenue in Q1 FY27?
Sigachi Industries Limited reported revenue of ₹98 crore for the quarter ended June 2026 (Q1 FY27), down 11.4% from ₹111 crore in the same quarter last year, and up 6.7% sequentially over the March 2026 quarter.
What was Sigachi Industries Limited's net profit in Q1 FY27?
The company swung to a net profit of ₹7 crore from a net loss of ₹99 crore a year earlier. Earnings per share (EPS) came in at ₹0.17.
What is SIGACHI's market capitalisation and P/E ratio?
At the current price of ₹27.52, SIGACHI has a market capitalisation of ₹1,053 crore and a trailing P/E of about 40.3.
Who owns Sigachi Industries Limited? (shareholding pattern)
As of Jun 2026, promoters held 36.69%, foreign institutional investors (FIIs) 1.25%, public shareholders 62.05% of Sigachi Industries Limited.
TTM ends 2026-06-30. Amounts are ₹ crore unless stated otherwise. Figures are extracted by AI from public quarterly filings; gaps are filled from public market data. Live price refreshed about twice a day from exchange data. Educational information only — not financial advice.
⚠️ How this site is made: Market data pages are computed automatically from NSE/BSE publications and company filings; news articles and announcement analyses are written with AI assistance, with a human in the loop: our editors review what the AI produces. Both can contain errors. Verify with the original sources before any investment decision. Not investment advice; Flash Finance is not SEBI-registered. How we use AI